Wen Liu

Wen Liu

Auto-generated profile, based on publicly available information

Wen Liu

Zentalis Pharmaceuticals, Inc., San Diego, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progression, including activation of WEE1-dependent cell cycle checkpoints. If DNA damage occurs during replication, the WEE1 checkpoint is activated, thereby preventing the progression of the cell cycle. This allows damaged DNA to be repaired before cells enter mitosis, or if the damage is too extensive, induction of apoptosis. These observations have made WEE1 a promising anticancer therapeutic target. Azenosertib (ZN-c3) is a novel, selective, and orally bioavailable WEE1 inhibitor. The antiproliferative activity of azenosertib on cancer cell lines is consistent with a WEE1-dependent mechanism of action exemplified by reduction of pY15-CDK1 levels and increases in DNA damage markers. Azenosertib further exacerbates the effect of replicative stress and DNA damage by allowing cancer cells to prematurely enter mitosis, leading to mitotic catastrophe and apoptosis. Azenosertib has optimized pharmacokinetic and pharmacodynamic properties, yielding robust tumor growth inhibition in a broad range of tumor models, and is highly effective at delaying the duration of tumor regrowth after cessation of treatment. We have explored various dosing schedules in preclinical efficacy models for azenosertib that preserve antitumor activity with minimal toxicity. Phase I studies with azenosertib as monotherapy have shown preliminary clinical activity in patients with advanced solid tumors. The data presented herein support further studies of azenosertib monotherapy across multiple solid tumor indications.

1 August 2025
Verified
Other
Open access
PDF file
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Supplementary Figure S1: Evaluation of azenosertib in cellular assays.

1 August 2025
Verified
Other
Open access
PDF file
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Supplementary Figure S2: Cytometric analysis of cell lines treated with azenosertib.

1 August 2025
Verified
Other
Open access
PDF file
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Supplementary Figure S3. Azenosertib efficacy in solid tumor xenograft models.

1 August 2025
Verified
Other
Open access
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Supplementary Table S2: List of proteins and protein modifications which in vitro expression is nominally (P-value<0.05) associated with in vivo response in pan-cancer, breast or lung NSCLC models

1 August 2025
Verified
Other
Open access
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Supplementary Table S6: Distribution of cells according to γH2Ax status in both treatments conditions (A) or in azenosertib treated cells in different cell cycle phase (B) or mitotic (C) context for each cell lines.